Pilot study on the safety and feasibility of intravenous opioid agonist therapy (OAT) with Hydagelan® (hydromorphone hydrochloride) in Vienna.
This study, happening in Vienna, is exploring a new way to help people who are dependent on opioids. Opioid dependence is a serious, long-term health condition that affects both the mind and body, and can lead to other health problems. The study is testing a medication called Hydagelan, given directly into a vein (through a drip), to see if it's safe and if it can be practically used in a treatment setting. The main goal is to see if this treatment helps people use fewer illegal opioids. Researchers are also looking at whether it helps reduce the use of other drugs, improves overall health, and encourages people to stay in treatment.
De un vistazo
¿De qué trata este estudio?
This study is about finding better ways to help people who are struggling with opioid dependence. Opioid dependence is a very serious health condition where a person relies on opioids, which can be prescription pain relievers or illegal drugs like heroin. It's not just a physical problem; it affects a person's thoughts, feelings, and overall life. People living with opioid dependence often face other health issues and sadly, it can even shorten lives.
The study is testing a new form of treatment called opioid agonist therapy (OAT) using a medication called Hydagelan. This medication is given directly into a vein, like you might have a drip in a hospital. The medical team wants to find out if giving Hydagelan this way is a safe and practical option for people. They are hoping it will help people reduce how often they use illegal opioids.
Beyond just reducing illegal opioid use, the study also aims to see if this treatment helps people cut down on other drugs, improves their general health and wellbeing, and encourages them to stay in their treatment programme. This type of research, called a Phase II study, is an early step in testing new treatments to make sure they are safe and could be helpful for patients.
Puntos clave
- The study is testing a new treatment called Hydagelan for opioid dependence.
- It's exploring if giving Hydagelan through a drip is safe and practical.
- A main goal is to help people reduce their use of illegal opioids.
- The study will also look at overall health improvements and treatment retention.
- It's an early-stage study, meaning more research will be needed in the future.
¿Quién puede ser elegible?
To join this study, participants must be at least 18 years old. Both men and women are welcome to take part.
More specific details about who can join will be provided by the study team. For example, they will need to check your medical history to make sure the treatment is suitable and safe for you.
It's important to discuss your full medical background and any medications you are currently taking with the study doctor to see if you are a good fit for this research.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- ¿Eres un hombre o una mujer?
- Do you have opioid dependence?
- Are you willing to receive medication through an intravenous drip?
- Can you commit to regular clinic visits for treatment and check-ups?
¿En qué consiste la participación?
If you decide to take part in this study, you would first have a full health check-up to make sure the treatment is right for you. The main part of the treatment involves receiving the study medication, Hydagelan, directly into a vein (like a drip). The strength of the medication will be one of three options: 50 mg/ml, 10 mg/ml, or 20 mg/ml solution. The research team will regularly check your health and how you are responding to the treatment. They will also keep track of your opioid use and any other drug use. This involves regular visits to the clinic for assessments and to receive your treatment. The total duration of the study, including how long you would receive treatment and how long they will follow up with you afterwards, would be fully explained by the study team.
Riesgos y beneficios potenciales
Ubicaciones (1)
- —No verificadoAustria
Preguntas comunes
What is opioid dependence?
Opioid dependence is a serious health condition where a person's body and mind rely on opioids, affecting their health and daily life.
What is Hydagelan?
Hydagelan is a medication being tested in this study as a treatment for opioid dependence, given through a drip.
What does 'intravenous' mean?
Intravenous means the medication is given directly into a vein, usually through a small tube or drip.
Will this study help me stop using drugs completely?
This study aims to help reduce the use of illegal opioids and improve health, but it's part of a broader treatment approach.
¿Puedo abandonar el estudio en cualquier momento?
Yes, you have the right to leave the study at any point without it affecting your usual medical care.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.